{"analyses":[{"ciLowerLimit":"0.129","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.587","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0004","paramType":"Hazard Ratio (HR)","paramValue":"0.275","statisticalComment":"Stratified by RET mutation type (M918T vs. Others) and intended treatment if randomized to Arm B (Vandetanib vs. Cabozantinib).","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Data not available due to high censoring.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Upper level Confidence Interval not available due to high censoring.","groupId":"OG001","lowerLimit":"10.41","upperLimit":"NA","value":"16.56"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"DoR by BICR is defined as the time from the date that measurement criteria for complete response (CR) or partial response (PR) (whichever is first recorded) are first met by the BICR or investigator assessment, as applicable, until the first date that disease is recurrent or documented disease progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"160 milligrams Selpercatinib administered orally (PO) twice daily (BID).\n\nAdolescent Dose: 92 mg/m2 BID (not to exceed 160 mg BID).","id":"OG000","title":"Selpercatinib (TRT A)"},{"description":"140 mg Cabozantinib administered orally daily (QD) or 300 mg Vandetanib administered orally QD per physician choice.\n\nCabozantinib Adolescent Dose: 40 mg/m2.\n\nVandetanib Adolescent Dose:\n\n* 0.7 - \\<0.9 - 100 mg every other day (QOD)\n* 0.9 - \\<1.2 - 100 mg QD\n* 1.2 - \\<1.6 - 7-day schedule 100 mg - 200 mg - 100 mg - 200 mg - 100 mg - 200 mg - 100 mg\n* ≥1.6 - 200 QD","id":"OG001","title":"Cabozantinib or Vandetanib (TRT B)"}],"paramType":"MEDIAN","populationDescription":"All randomized participants, even if a participant did not take the assigned treatment, did not receive the correct treatment, or otherwise did not follow the protocol. Censored participants: Selpercatinib - 119, Cabozantinib or Vandetanib - 25","reportingStatus":"POSTED","timeFrame":"Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 39 Months","title":"Duration of Response (DoR) by BICR","type":"SECONDARY","unitOfMeasure":"Months"}